Lysosomal storage diseases are a group of approximately 50 disorders in which hematopoietic stem cell transplantation is a potential treatment option. This is based on the ability of cells to excrete the enzyme and to cross-correct recipient cells. In vitro and animal model studies form the basis for risky clinical trials. According to present experience, the outcome of transplantation depends on the specific enzyme and timing of transplantation in relation to the disease onset. In most studied cases, the pathology is reversed in the visceral organs, whereas success in central nervous system varies or is unclear.
In mucopolysaccharidosis type 1 (Hurler syndrome), neurological improvement has been demonstrated in addition to alleviation of visceral symptoms, in a subset of transplanted patients. The skeletal lesions seem to be resistant to transplantation. Transplantation should, however, be performed preferably before the age 18 months. In metachromatic leukodystrophy, stabilization of neuropsychiatric function, but continued progression of peripheral nerve dysfunction and cerebellar deterioration has been reported. However, in early-onset form the presymptomatic timing of transplantation is necessary. Also, in infantile form of Krabbe disease, successful immediate postnatal transplantation necessitates early diagnosis. 1 In aspartylglucosaminuria (AGU) we have previously analyzed the biochemistry and cell biology of the disease enzyme: lysosomal aspartylglucosaminidase (AGA) (reviewed in Aula et al 2 ). Importantly, recent analyses have shown that AGA is efficiently exocytosed by donor cells and endocytosed by recipient cells in vitro, especially in primary glial cell culture and also in neuronal cultures. In that study we used primary cells derived from the AGU mouse and overexpression of AGA with adenoviruses containing tissue-specific promoters. Interestingly, human AGA promoter was found to be a very powerful glia promoter. 3 We have also used adenovirus for overexpression of AGA in vivo in AGU mouse brain resulting in partial correction of brain pathology. 4 The AGU mouse model presents tissue pathology similar to humans including lysosomal storage in all tissues. 5 In our earlier BMT study we documented correction of lysosomal storage in AGU mouse liver and spleen, but not in brain and kidney. 6 The mice were, however, transplanted as 8-week-old adults.
In human AGU patients the main symptom is progressive mental retardation. Other features include coarse facial features, hepatosplenomegaly, recurrent infections in childhood, motor clumsiness, seizures and arthritis. 2 BMT has been performed in a few AGU patients with poor outcome on neurological deterioration. All of the BMTs, however, have been performed after infancy using heterozygote carrier siblings as donors having only approximately 50% AGA enzyme activity. 7 In this study we used young 3-week-old AGU mice as recipients of BMT and wanted to test the effect of a heterozygote carrier donor with 50% enzyme activity vs a wild-type donor with normal enzyme activity. Irradiated 3-week-old AGU mice were transplanted with 2 Â 10 6 fresh bone marrow cells harvested from normal C57BL or heterozygote AGU/C57BL donors. As controls we used AGU mice transplanted with marrow harvested from AGU donors and normal C57BL mice. The mice were killed for investigation 6, 8 and 10 months after transplantation in both groups. The success of transplantation was analyzed by culturing marrow cells in methyl cellulose to generate hematopoietic colonies in which wild-type cells and AGU mouse cells could be distinguished by genomic PCR as described earlier. 6 In studied animals, approximately 70-80% of the colony-forming unit granulocyte-macrophage (CFU-GM) were found to be donor-derived.
Lysosomal storage vacuoles were analyzed by light microscopy from PFA-perfused and glutaraldehyde-postfixed liver and brain thin sections embedded in epoxy resin and stained with toluidine blue. In liver, total correction of lysosomal vacuolization was found in AGU animals receiving BMT from normal donors, but in the heterozygote donor group correction was surprisingly not complete in most animals. In the brain, thalamic and cerebral cortical regions were examined for storage vacuoles. In normal donor group, partial but clear 80% reduction of vacuolated neurons was detected in thalamic region and 30% reduction was detected in parietal cortex 8 and 10 months after BMT (Figure 1 ). In the heterozygote donor group only 40% reduction of vacuolated neurons was found in thalamus and in parietal cortex vacuoles appeared at the same extent as in untreated control mice. There were no vacuoles in glial cells, but they are not easily detectable even in untreated mice.
Immunostaining was used to analyze the active lysosomal AGA enzyme in treated mouse brain. In untreated AGU mouse brain there is only inactive nonlysosomal background AGA positivity. Frozen sections were doublestained with AGA antiserum and lysosomal marker (Lamp-1) (Figure 2 ) or microglial marker (Mac-1). Colocalization was found with both markers in wild-type BM treated mice but not in mice transplanted with AGU BM. Positive AGA staining was seen also in cell types other than microglia demonstrating the ability of AGA to migrate in brain tissue. AGA enzyme activity in treated mouse brain was however below the threshold of AGA activity assay.
In this study we could demonstrate that the outcome of marrow transplantation in AGU was more favorable by using young recipients and donors with normal enzyme activity. We cannot know what kind of effect the clearance of storage material in brain would have on psychomotor deterioration in human patients. The difference between normal and AGU mice in behavioral tests is so small that those tests cannot be used to evaluate the effect of enzyme correction. 5, 8 We can, however, assume that correction of the lysosomal vacuolization in the affected tissues would be the minimum demand for potential cure.
The outcome in neurological function is crucial in lysosomal storage diseases, mental regression being the leading symptom in most of them. The presence of donorderived cells in the cerebrospinal fluid demonstrating crossing the blood-brain barrier was documented already in 1985 by Bayever et al. 9 The marrow-derived microglial cells represent approximately 20% of glial cells in the brain and 30% of microglial cells have been shown to be of donor origin 1 year after transplantation in a mouse model. 10 In AGU we have estimated that about 5% of the wild-type enzyme activity would be enough to correct the tissue pathology. 6 Thus, without overexpression the donor carrier status may be crucial for the outcome of marrow transplantation. In possible future transplantations to AGU patients only noncarrier family donors or unrelated donors should be used. Timing of transplantation in relation to the disease onset is another important issue. 
